SPHK2 and non-small cell lung carcinoma: SphK2 inhibition, by a small molecule inhibitor ABC294640, enhanced TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced antitumor activity in NSCLC cells [17].